CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

ASCO26: In vivo oncology approaches continue to show promise

ConferencePositive
AI Analysis

Summary

Eli Lilly's $7 billion acquisition of Kelonia is showing positive results with in vivo oncology approaches demonstrating promise at ASCO 2026.

Importance:5/10
Sentiment:
0.70
ASCO 2026in vivo oncologyacquisitionclinical data
Related Companies

Read the original article

Published by Clinical Trials Arena on June 2, 2026 2:47 PM

Read Original